US Clinical Labs To Lose Money On COVID-19 Testing Without $5Bn Set Aside In Third $1Tn Aid Bill
A $5bn emergency fund reimbursing US clinical laboratories for scaling up COVID-19 testing with lab-developed tests must be part of a $1tn Senate coronavirus aid and relief package, clinical lab group ACLA says. Other provisions already included in the draft bill address stockpiling of testing swabs, liability protection for medtech firms, a requirement for device makers to report supply chain shortages, the expanded use of telehealth, and preventing durable medical equipment payment reductions.
You may also be interested in...
CMS Doubles Up On Test Reimbursements, Will Pay Labs $100 Per Test For COVID-19 Clinical Diagnostic Assays
The US Medicare agency said on 15 April it will double its reimbursement rate for certain COVID-19 lab tests.
An interim final rule posted by the CMS this week widens further a series of telehealth exemptions and lab specimen collection payment provisions it has previously issued to help providers during the COVID-19 pandemic.
The US Department of Health and Human Services is offering some legal protection to developers of devices and diagnostics for use in the fight against the novel coronavirus.